Literature DB >> 8763439

Mycosis fungoides with extracutaneous localization in the breast.

L H Jaspars1, P Bonnet, R Willemze, C J Meijer.   

Abstract

We report a patient with mycosis fungoides (MF) and transformation to anaplastic (CD30+) lymphoma, who developed an unusual manifestation in the breast. Cutaneous and extracutaneous tumour cells both showed marked intraepithelial migration, but had distinct expression patterns of epitheliotropism-associated integrins. Intraepidermal and dermal lymphoma cells in the skin expressed most of the integrins that are presumed to be involved in epitheliotropism, such as leucocyte functional antigen-1 (LFA-1), alpha 1 beta 1, alpha 3 beta 1, alpha 4 beta 1 and alpha 6 beta 1. In the breast, most of the extraepithelial tumour cells only expressed the laminin-5 ligand alpha 3 beta 1 (strong) and the collagen ligand alpha 1 beta 1 (weak). However, on the intraepithelial tumour cells in the mammary ducts and glands LFA-1, alpha 4 and alpha E could also be detected. In view of these findings we propose epitheliotropism of the MF cells in the breast to be a multistep process in which tumour cell-epithelial basement membrane (EBM) interaction, predominantly mediated by alpha 3 beta 1 and laminin-5, is the primary event. Adhesion to and subsequent infiltration of the neoplastic lymphoid cells into the EBM may, either directly or indirectly, lead to upregulation and/or activation of other integrins that amplify interaction with epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763439

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  1 in total

1.  Pancreatic metastasis from mycosis fungoides mimicking primary pancreatic tumor.

Authors:  Paola Ceriolo; Valentina Fausti; Elisa Cinotti; Silvia Bonadio; Lizzia Raffaghello; Giovanna Bianchi; Giulio Fraternali Orcioni; Roberto Fiocca; Franco Rongioletti; Vito Pistoia; Giacomo Borgonovo
Journal:  World J Gastroenterol       Date:  2016-03-28       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.